期刊
INTERNATIONAL JOURNAL OF HEMATOLOGY
卷 108, 期 4, 页码 365-370出版社
SPRINGER JAPAN KK
DOI: 10.1007/s12185-018-2519-y
关键词
BCR-ABL; Chronic myeloid leukemia; Leukemia stem cells; Tyrosine kinase inhibitors
类别
资金
- National Institute of Biomedical Innovation
- Ministry of Education, Culture, Sports, Science and Technology on Scientific Research, Japan
Chronic myeloid leukemia (CML) is effectively treated with tyrosine kinase inhibitors (TKI) targeted against BCR-ABL. We previously reported the investigation of residual CML diseases during TKI treatment using FACS-sorting and quantitative RT-PCR of BCR-ABL among each population; total mononuclear cells, hematopoietic stem cells, and myeloid progenitors. The observations also implied that the second-generation of ABL-tyrosine kinase inhibitors (2nd TKIs), dasatinib or nilotinib therapy can be more promising approach for efficient reduction of the CML stem cells. Moreover, we need to develop the evaluation method of the residual CML diseases to establish rational therapy-cessation strategies in CML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据